|
105 Piccadilly London W1J 7NJ, United Kingdom Tel. +44-20-7491-1777 Fax +44-20-7491-3338 |
Type: Public
On the web:
http://www.skyepharma.com
There's good karma for aging pharmaceuticals at SkyePharma. The company uses its controlled-release drug delivery technologies for inhaled, oral, and topical drugs to produce more effective versions of already proven therapies. It makes money from partnerships with other pharmaceutical companies, such as GlaxoSmithKline and Sciele Pharma, who seek out SkyePharma's drug delivery expertise. The firm also develops some compounds on its own and then licenses them to others for marketing. Its lead proprietary candidate is Flutiform, an inhaled treatment for asthma and chronic obstructive pulmonary disease (COPD).
Key numbers for fiscal year ending December, 2008:
Sales: $90.0M
One year growth: 8.4%
Net income: ($41.5)M
Officers:
Chairman: Jeremy P. Scudamore
CEO and Director: Ken Cunningham
CFO and Director: Peter W. Grant
Competitors:
Alkermes
Elan
Theravance
